INPEFA® is an inhibitor of SGLT2 and SGLT1 for adults with heart failure or T2 Diabetes, CKD, and other CV risk factors. See Safety Info and full Prescribing Information.

A multi-center, randomized, double-blind, placebo-controlled, Phase 3 study in 10,584 patients with T2DM, CKD, and additional CV risk factors, evaluating the HF outcomes of INPEFA versus placebo …

Learn about the financial support options and helpful resources that INPEFA® offers your patients, like the 30-day voucher and copay card. See Important Safety Information and full Prescribing Information.

Asserts that INPEFA significantly reduced the risk of CV death, hospitalization for HF, and urgent HF visit when compared to placebo as evaluated in SOLOIST‑WHF

Learn how INPEFA® was studied in patients with heart failure and view information about the SOLOIST-WHF trial. See Important Safety Information and full Prescribing Information.

Our digital pharmacy partner Blink Health (1-844-265-6444) automatically gets you started with your free 30-day supply of INPEFA. INPEFA TogetherTM will reach out to confirm delivery to your home or …

All patients receive a voucher for a free 30-day supply* of INPEFA as prescribed by their doctor. Enrollment in the 30-Day Voucher Program triggers support through INPEFA TogetherTMM.

INPEFA dosing for patients with decompensated heart failure may begin when patients are hemodynamically stable, including when hospitalized or immediately upon discharge.

Derived From: Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie …